Gothenburg,September 16, 2019- On September 11, 2019, Vicore Pharma Holding AB (publ) (”Vicore” or the “Company”)  announced that Nasdaq Stockholm’s listing committee had approved that the Company’s shares are admitted to trading on Nasdaq Stockholm’s main market. Today, on Sept... read more

Stockholm – September 15, 2019 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today updated interim efficacy and safety data from the ongoing pivotal Phase 2 study, HORIZON, at the 17th International Myeloma Workshop (IMW) meeting in Boston, Massachusetts, USA. The data focused on ... read more

Stockholm – September 11, 2019 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that clinical trial data were presented at the Society of Hematologic Oncology (SOHO) 2019 Annual Meeting in Houston, TX, USA. In an oral presentation, data from the pivotal Phase 2 HORIZON clinical tri... read more

Gothenburg, September 11, 2019 – Nasdaq Stockholm’s listing committee has approved Vicore Pharma Holding AB (publ)’s (”Vicore”) application to be listed on Nasdaq Stockholm’s main market, subject to customary conditions. The last day of trading on Nasdaq First North Growth Market is ... read more

GAITHERSBURG, Md., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced it has appointed M. Scott Harris, M.D. as Chief Medical Officer. Dr. Harris is succeeding Dr. Sybil Tasker, who resigned June 30, 2019 to continue ... read more